·Basic Research· ·Current Issue· ·Achieve· ·Search
Articles· ·Online
Submission· ·About IJO· PMC
Analysis of the effective dose of ultraviolet light in corneal cross-linking
Yong Zhang1, Kuan-ChenWang2, Chao-Kai Chang3, Jui-Teng Lin4
1Department of
Ophthalmology, Shandong Provincial Hospital, Shandong University, Jinan 250021, Shandong
Province, China
2Department of Electronic
Engineering, Taiwan University, Taipei, Taiwan 101, China
3Nobel Eye Institute,
Taipei, Taiwan 101, China
4New Vision Inc., Taipei, Taiwan 103
and Gong-Rui Medical Technology Corp, Xiamen, Fujian Province, China
Correspondence to: Jui-Teng Lin. New Vision Inc., Taipei, Taiwan 103, China.
jtlin55@gmail.com
Received:
2015-05-19
Accepted: 2016-01-06
Abstract
AIM:
To analyze the efficacy of ultraviolet (UV) light initiating corneal
cross-linking (CXL).
METHODS: The time-dependent
absorption of UV light due to the depletion of the initiator (riboflavin) was calculated. The effective dose of CXL with corneal surface covered by a
thin layer of riboflavin was derived analytically. The cross linking time was calculated by the depletion level of the riboflavin concentration. A
comprehensive method was used to derive
analytic formulas.
RESULTS: The effective dose of CXL was reduced by a factor (R) which
was proportional to the thickness (d) and concentrations (C0) of the
riboflavin surface layer. Our calculations showed
that the conventional dose of 5.4 J/cm2 had a
reduced effective dose of 4.3 and 3.45 J/cm2, for d was 100 and 200 μm, respectively, and C0=0.1%. The surface cross
linking time was calculated to be T*=10.75s, for a depletion level of 0.135 and
UV initial intensity of 30 mW/cm2. The volume T* was exponentially
increasing and proportional to exp (bdC0), with b being the steady
state absorption coefficient.
CONCLUSION: The
effective dose of CXL is reduced by a factor proportional to
the thickness and concentrations of the riboflavin surface layer. The wasted
dose should be avoided by washing out the extra riboflavin surface layer prior
to the UV light exposure.
KEYWORDS:
keratoconus; collagen corneal
cross-linking; ultraviolet radiation; riboflavin; safety efficacy
DOI:10.18240/ijo.2016.08.01
Citation:
Zhang Y, Wang KC, Chang CK, Lin JT. Analysis of the effective dose of
ultraviolet light in corneal cross-linking. Int
J Ophthalmol 2016;9(8):1089-1093
INTRODUCTION
Photo-polymerization has
been used in chemical engineering applications[1-4] and
more recently for corneal cross-linking (CXL)[5-14]. However, much fewer
efforts have been invested in basic theoretical studies[15-19]. Many factors can affect
the CXL reaction and the amount of biomechanical stiffness
achieved. These factors include riboflavin concentration, condition of the
cornea, temperature, presence of the oxidizing agent (riboflavin), the
ultraviolet (UV)
light intensity, its dose and the on-off duty cycle. The safety and efficacy of
CXL have been reported clinically by various methods, including the accelerated
CXL using high UV power, pulsed mode operation for
improved oxygen supply, diffusion in the
de-epithelialized stroma (standard method),
diffusion through the epithelium into the stroma (transepithelial method), or direct introduction of riboflavin into the stroma (pocket
technique, ring technique, needle technique), and
enrichment of riboflavin in the stroma by iontophoresis[20-21].
The conventional CXL
procedures are based on the Dresden protocol which requires a surface safety
dose of 5.4 J/cm2 and a minimum corneal thickness of 400 µm. During the UV exposure, riboflavin drops were applied
every few minutes for saturated riboflavin concnetraion in the stroma and extra
protection of the corneal endothelial cells. However, the effective dose of CXL
is reduced by the extra absorption of this surface layer. For maximum efficacy,
the wasted-dose can be avoided by washing out the extra surface riboflavin
layer after its sufficient diffusion into the stroma and prior to the UV light
exposure. The dynamic in the stroma has been studied elsewhere[18-19] and this paper will focus
on the riboflavin surface layer and its influence on the efficacy of CXL. We
shall note that previous study[15] assuming a
time-independent riboflavin concentration, or without the depletion feature,
would underestimate the steady-state intensity and hence overestimate the safety
dose. The riboflavin depletion plays the major role of the dynamic feature of
CXL.
We will also introduce a CXL time defined by the duration of light exposure needed
for riboflavin concentration depletion to exp (-M) of its initial value, with M
is 2 to 4. The dynamic in the stroma has been studied elsewhere[16-19], this paper will focus on
the role of the B2 surface layer.
MATERIALS AND METHODS
The Modeling System As shown in Figure 1, a simplified corneal model consists of its
epithelial layer and the underlying stroma collagen, where z represents corneal
thickness and z=d defines the corneal surface. The UV light is incident-normal
to the corneal surface, which is covered by a thin layer of riboflavin (or B2) solution. The CXL procedures could be conducted
either with epithelium off (epi-off) with a 0.1% riboflavin-dextran solution or
with epithelium on (epi-on) with a 0.25% riboflavin aqueous solution. The
riboflavin penetration depth in the epi-on case is normally less than that for
epi-off due to the less efficient diffusion (f) riboflavin in the epi-on case. This paper will discuss the
epi-off case and the influence of the surface B2 layer (Figure 1). The dynamic in the stroma (z>d) has been
studied elsewhere[16-19], this paper will focus on
the role of the B2 surface layer, or z<d.
Figure 1 A corneal model system for the initial distribution of the riboflavin
surface layer (z<d) and inside the stroma (z>d).
The Dynamic Equations In the above-described
corneal modeling system, the concentrations of the B2 photoinitiator C(z,t) and
the UV light intensity I(z,t) inside the B2 surface layer or inside the stroma
may be described by coupled integral equations (Eq.) as follows [1-2,16]:
(1b)
where F(z) is the distribution profile of the initial B2
solution (Figure
1) with F(z)=1, for z<d; , with φ being the quantum yield, λ being the UV
light
wavelength; a and b being the molar extinction coefficients of the riboflavin
(initiator) and the photolysis product, respectively. Q is the absorption coefficient
of the corneal stroma tissue reported to be Q=32 cm-1
without the epithelium[13]. The extinction coefficient of the
riboflavin (or
B2) solution
(at 365 nm) has been reported[12,15] as a=469 (%·cm)-1 and extinction coefficients of the photolysis
product[19] b is about 40% to 60% of a, or b=(188-263) (%·cm)-1. The following units are
used: C(z,t) in
weight percent (%), I(z,t) in (mW/cm2), λ in cm, a and b in (%·cm)-1.
The above coupled equations will be solved
analytically and numerically under the initial and boundary conditions C (z=0,
t=0)=C0 and I (z=0, t=0)=I0[19-20].
We shall note that previous study[15] using Eq.(1a) for the
UV intensity and assuming a time-independent B2 concentration, or without the
second coupled Eq.(1b), would underestimate the steady-state intensity and also
the safety dose. The B2 depletion defined by Eq.(1b) plays the major role of
the dynamic feature of CXL.
Our
goal is to study the role of the B2 surface layer on the efficacy of CXL. For
uniform B2
surface layer on top of the stroma (with z<d, shown in Figure
1), there is no stroma
absorption (c=0)
and only the
extinction coefficients of the riboflavin (initiator) (a) and the photolysis product
(b) are needed in Eq.(1). In addition, for the B2 surface layer,
F(z)=1 for a uniform distribution.
Analytic approximate
solution of Eq.(1) and (2) leads to the UV light intensity given by a revised
time-dependent Lambda-Beer law [19]:
(2)
Where the time-dependent
extinction coefficient A(t) shows the dynamic feature of the UV light
absorption due to the B2 concentration depletion. This feature will be shown
both theoretically and experimentally later.
The exact UV light
intensity profiles require numerical solution of Eq.(1). However, the initial
and steady state solutions are analytically available as follows[16]:
(3)
With
A1=aC0 for the initial state and A2=bC0 for the steady state for Q=0 in the B2 surface layer.
For
a comprehensive method,
as shown by Figure 2, the
time integration function
E(d,t), or the area covered by the red line of Figure 2, defines the dose absorbed by the B2
surface layer (with thickness d) for an exposure time (t). Therefore the
effective dose is given by
(4a)
where
the dose reduction factor (R) is approximated by the steady-state formula[16]
(4b)
and
E0=tI0 is the dose applied on the corneal surface (at
z=0) with a reduction factor defined by R=Eeff/E0.
Figure 2 Schematic of the light intensity I(z,t) profiles at a given depth (z)
in the transient (for t<t* ) and steady state (for t>t*) defined by
Eq.(3).
The
Cross-linking Time CXL time
may be defined in a variety of ways. Basically, it is used to define the level of depletion of the B2 initial
concentration and the procedure reaches a steady state having a very low
reaction rate. Based on the above-described concept, we define the CXL time (T*) as when
the B2
concentration on the is reduced to C(z,t)=C0exp(-M), at t=T*, where M has a value ranging from 2 to 4 depending
on the depletion level of the B2 concentration at a depth z.
The solution of Eq.(1) and (2) to solve for t=T* is highly nonlinear and
cannot be solved analytically.
Numerical results will
be shown elsewhere. Using
Eq.(4) for the integration of Eq.(1.b), we
obtain
where
T0=M/(gI0) is the surface CXL time (at z=0). For a quantum efficiency
of 0.1, we have g=0.062, or T0=16.1M/(I0) with I0 in mW/cm2.
RESULTS
The Dynamic Intensity Profiles As shown in Figure 3, the initial intensity (solid curve)
increases due to B2 depletion and reaches its steady-state (dashed red curve)
defined by Eq.(3). The intensity has a faster exponential decay for z>d due
to the addition absorption of the corneal stroma, whereas for z<d the
absorption is due to B2 solution only. The dynamic in the stroma has been
studied elsewhere[19]. This paper will focus on the role of the
B2 surface layer, or z<d.
Figure 3
Schematics of the light intensity initially (solid curve) and at steady-state
(dashed red curve).
Figure 4 shows the calculated time-dependent UV light intensity at a given position
z=200 μm for various B2 initial concentration C0=(0.1,
0.15, 0.2)% (from top to low curves), where we have used a=469 (%·cm)-1, Q=32 cm-1 and b=0.5a.
Figure 4 The calculated light intensity (normalized by its initial value)
at a given depth z=200 μm for various riboflavin concentration C0=(0.1, 0.15,
0.2)% (from top to low curves).
The
calculated time increasing feature of the UV light intensity is consistent with
our measured data shown by Figure 5. The measured UV light transmitted intensity (normalized by its
initial value) showing the time increasing feature, where the initial riboflavin
concentration is 0.0075% (top curve) and 0.005% (lower curve)[18].
Figure 5 The measured UV light transmitted intensity for riboflavin
concentration of 0.0075% (top curve) and 0.005% (lower curve).
The Cross-linking Time As shown by Figure 6, the initial constant concentration
(curve 1) is depleted to lower curves (2 to 7) at various time of t=(5, 10, 20,
40, 60, 80)s, for an initial concentration of C0=0.2%. We may easily
see that the B2 depletion starts from the surface. It takes longer exposure
time to deplete the volume layer and the cross linking time (T*) is given by
Eq.(5). Also shown in Figure 6 is the red line defined by a depletion level of
C/C0=0.135, or exp(-M) with M=2. The cross points of the red line
and the concentration curves defines the cross linking time (T*) for various
depth of the B2 layer. The corresponding dose, defined by E*=T*I0,
for various concentration of C0=(0.1, 0.15, 0.2, 0.25 0.3)% for
curves left to right (Figure
7).
Figure 6 The normalized B2 concentration at various time
t=(0, 5, 10, 20, 40, 60, 80)s (for curve 1 to 7), for an initial concentration
C0=0.2%.
Figure 7 The required dose to deplete the B2 layer at
various thickness (d), for various concentration of C0=(0.1, 0.15,
0.2, 0.25, 0.3)%, (curves left to right), for a=469 (%·cm)-1,
b=0.5a,
Q=32 cm-1.
The Effective Dose As shown by Eq.(4), the dose applied on the corneal
surface (at z=0) E0=tI0 is reduced by a factor R due to
the dose absorbed by the B2 surface layer (with thickness d), where R=Eeff/E0
is given by Eq.(4b). For b=235(%·cm)-1 and Q=32 cm-1, we calculate the reduction
factor, for R=(0.8, 0.64), for d=(100, 200) μm and C0=0.1%,
which is further decrease to R=(0.64, 0.41), for C0=0.2%.
The effective dose given by
Eq.(4) defines the available dose at z=d after the absorption of the B2 layer.
That is, less CXL efficacy in thicker B2 surface layer with high concentration.
At steady state, or when the B2 layer is largely depleted, the UV light surface
intensity (I0) is reduced to I0exp(-bC0d), as
shown by Eq.(4b). For example, the conventional dose 5.4 J/cm2 is
reduced to an effective dose of 5.4×0.8=4.3 J/cm2, that is 20% of the dose, or 1.08 J/cm2 dose is wasted in the B2 surface layer
having a thickness of 100 μm and concentration of
0.1%. The effective dose is further reduced to 5.4×0.64=3.45
J/cm2 for a thicker B2 layer of 200 μm.
The cross linking time
(T*) defined by the depletion of the riboflavin is given by Eq.(5). The surface
CXL time (at z=0) given by T0=M/(gI0) is calculated T*=10.75s,
for M=2 and g=0.0062 (for a quantum efficiency of 0.1) and UV initial intensity
of 30 mW/cm2. While B2 surface layer provides extra protection of
the corneal endothelial cells, the wasted dose (defined by 1-R) should be avoided
by washing out the extra B2 surface layer after its sufficient diffusion into
the stroma and prior to the UV light exposure. As shown earlier, a B2 layer of
100 and 200 μm causes the effective
dose reduced to 69% and 49%, respectively, for 0.1% concentration; and 48% and
25%, for 0.2% concentration.
In conclusion,
the effective
dose of CXL is reduced by a factor (R) which is proportional to the thickness
and concentrations of the riboflavin surface layer. For maximum efficacy, the
wasted dose (defined by R) should be avoided by washing out the extra B2
surface layer.
ACKNOWLEDGEMENTS
Foundations: Supported
by an internal grant from New Vision Inc.; Talent-Xiamen (XM-200) Program (Xiamen Science & Technology Bureau,
China).
Conflicts of Interest: Zhang Y, None; Wang KC, None; Chang CK, None; Lin JT, None.
REFERENCES [Top]
1 Odian G. <ii>Principles of
Polymerization</ii>. Wiley, New York, 1991. [PubMed]
2
Miller GA, Gou L, Narayanan V, Scranton AB. Modeling of photobleaching for the
photoinitiation of thick polymerization systems. <ii>J Polym Sci Pol
Chem</ii> 2002;40(6):793-808. [CrossRef]
3
Lin JT, Liu HW, Cheng DC. Modeling the kinetics of enhanced
photo-polymerization under a collimated and a reflecting focused UV laser.
<ii>Polymers </ii> 2014;6(5):1489-1501. [CrossRef]
4
Lin JT, Cheng DC. Optimal focusing and scaling law for uniform
photo-polymerization in a thick medium using a focused UV Laser.
<ii>Polymers</ii> 2014;6(2):552-564. [CrossRef]
5
Meek KM, Hayes S. Corneal cross-linking-a review. <ii>Ophthalmic Physiol
Opt</ii> 2013;33(2):78-93. [CrossRef] [PubMed]
6
Kamaev P, Friedman MD, Sherr E, Muller D. Photochemical kinetics of corneal
cross-linking with riboflavin. <ii>Invest Ophthalmol </ii>Vis Sci
2012;53(4):2360-2367. [CrossRef] [PubMed]
7
Søndergaard AP, Hjortdal J, Breitenbach T, Ivarsen A. Corneal distribution of
riboflavin prior to collagen cross-linking. <ii>Curr Eye Res</ii>
2010;35(2):116-121. [CrossRef] [PubMed]
8 Spoerl E, Mrochen M, Sliney D, Trokel S, Seiler T. Safety of UVA-riboflavin
cross-linking of the cornea. Cornea 2007;26(4):385-389.
9 Lamy R, Chan E, Zhang H, Salgaonkar
VA, Good SD, Porco TC, Diederich CJ, Stewart JM. Ultrasound-enhanced
penetration of topical riboflavin into the corneal stroma. Invest Ophthalmol Vis Sci 2013;54(8):5908-5912. [CrossRef] [PubMed] [PMC free article]
10
Wollensak G, Spoerl E, Wilsch M, Seiler T. Endothelial cell damage after
riboflavin-ultraviolet-A treatment in the rabbit. J Cataract Refract Surg 2003;29(9):1786-1790. [CrossRef]
11
Wernli J, Schumacher S, Spoerl E, Mrochen M. The efficacy of corneal
cross-linking shows a sudden decrease with very high intensity UV light and
short treatment time. Invest Ophthalmol
Vis Sci 2013;54(2):1176-1180. [CrossRef] [PubMed]
12
Schumacher S, Mrochen M, Spoerl E. Absorption of UV-light by riboflavin
solutions with different concentration. J
Refract Surg 2012;28(2):91-92. [PubMed]
13
Koppen C, Gobin L, Tassignon MJ. The absorption characteristics of
the human cornea in ultraviolet-a crosslinking. Eye Contact Lens 2010;36(2):77-80. [CrossRef] [PubMed]
14 Hafezi F, Randleman JB. Corneal collagen
cross-linking. SLACK, NJ, 2013.
15
Schumacher S, Mrochen M, Wernli J, Bueeler M, Seiler T. Optimization model for
UV-riboflavin corneal cross-linking. Invest
Ophthalmol Vis Sci 2012;53(2):762-769. [CrossRef] [PubMed]
16 Lin JT. Analytic formulas for the clinical issues of a
UV-light-activated corneal cross-linking device. J Biomed Eng Devic 2016;1:104.
17
Lin JT. Analytic formulas on factors determining the safety and efficacy in
UV-light-sensitized corneal cross-linking. Invest
Ophthalmol Vis Sci 2015;56(10):5740-5741. [CrossRef] [PubMed]
18
Lin, JT, Liu HW, Cheng DC. On the dynamic of UV-light initiated corneal cross
linking. J Med Biol Eng
2014;34(3):247-250. [CrossRef]
19 Lin JT, Cheng DC, Chang CK, Zhang Y. The new protocol
and dynamic safety of UV-light activated corneal collagen cross-linking. Chin J Optom Ophthalmol Vis Sci
2015;17(3):140-147.
20
Shalchi Z, Wang X, Nanavaty MA. Safety and efficacy of epithelium removal and
transepithelial corneal collagen crosslinking for keratoconus. Eye (Lond) 2015;29(1):15-29. [CrossRef] [PubMed] [PMC free article]
21 Mazzotta C,
Traversi C, Caragiuli S, Rechichi M. Pulsed vs continuous light accelerated
corneal collagen crosslinking: In vivo qualitative investigation by confocal
microscopy and corneal OCT. Eye(Lond) 2014;28(10):1179-1183.
[CrossRef]
[Top]